MENU
+Compare
ERAS
Stock ticker: NASDAQ
AS OF
Jun 6, 04:59 PM (EDT)
Price
$1.60
Change
+$0.03 (+1.91%)
Capitalization
444.76M

ERAS Erasca Forecast, Technical & Fundamental Analysis

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers... Show more

ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ERAS with price predictions
Jun 05, 2025

ERAS's RSI Indicator ascending out of oversold territory

The RSI Indicator for ERAS moved out of oversold territory on May 29, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In of the 32 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 29, 2025. You may want to consider a long position or call options on ERAS as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ERAS just turned positive on May 30, 2025. Looking at past instances where ERAS's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

ERAS moved above its 50-day moving average on May 29, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ERAS crossed bullishly above the 50-day moving average on June 05, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in of 196 cases, the price rose further within the following month. The odds of a continued upward trend are .

ERAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ERAS entered a downward trend on June 04, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.113) is normal, around the industry mean (16.332). P/E Ratio (0.000) is within average values for comparable stocks, (59.787). ERAS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (263.647).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ERAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ERAS is expected to report earnings to rise 7.45% to -11 cents per share on August 07

Erasca ERAS Stock Earnings Reports
Q2'25
Est.
$-0.12
Q1'25
Beat
by $0.02
Q4'24
Beat
by $0.02
Q3'24
Beat
by $0.06
Q2'24
Missed
by $0.11
The last earnings report on May 13 showed earnings per share of -10 cents, beating the estimate of -12 cents. With 904.23K shares outstanding, the current market capitalization sits at 444.76M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
3115 Merryfield Row
Phone
+1 858 465-6511
Employees
126
Web
https://www.erasca.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NBSTX49.77N/A
N/A
Neuberger Berman Sustainable Equity Tr
FNKCX15.16N/A
N/A
Frank Value C
FIONX16.21N/A
N/A
Fidelity SAI International Index
BFTUX61.19N/A
N/A
Baron Fifth Avenue Growth R6
HOOSX28.20N/A
N/A
Hartford Schroders US Small Cap Opps R4

ERAS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+2.61%
RVMD - ERAS
56%
Loosely correlated
-0.42%
LRMR - ERAS
56%
Loosely correlated
+0.41%
XNCR - ERAS
54%
Loosely correlated
+0.22%
ATXS - ERAS
53%
Loosely correlated
-1.14%
APGE - ERAS
53%
Loosely correlated
+3.10%
More